143 related articles for article (PubMed ID: 38170337)
21. Mechanism of METTL14-mediated m
Gong S; Wang S; Shao M
J Mol Med (Berl); 2022 Dec; 100(12):1771-1785. PubMed ID: 36352154
[TBL] [Abstract][Full Text] [Related]
22. Downregulation of miR-33a-5p in Hepatocellular Carcinoma: A Possible Mechanism for Chemotherapy Resistance.
Meng W; Tai Y; Zhao H; Fu B; Zhang T; Liu W; Li H; Yang Y; Zhang Q; Feng Y; Chen G
Med Sci Monit; 2017 Mar; 23():1295-1304. PubMed ID: 28291769
[TBL] [Abstract][Full Text] [Related]
23. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer.
Li M; Chen W; Zhang H; Zhang Y; Ke F; Wu X; Zhang Y; Weng M; Liu Y; Gong W
Oncotarget; 2016 Dec; 7(50):83060-83070. PubMed ID: 27825112
[TBL] [Abstract][Full Text] [Related]
24. miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs).
Liu X; Zhou X; Chen Y; Huang Y; He J; Luo H
Neoplasma; 2020 Jan; 67(1):147-157. PubMed ID: 31686523
[TBL] [Abstract][Full Text] [Related]
25. Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway.
Fu X; Liu M; Qu S; Ma J; Zhang Y; Shi T; Wen H; Yang Y; Wang S; Wang J; Nan K; Yao Y; Tian T
J Exp Clin Cancer Res; 2018 Mar; 37(1):52. PubMed ID: 29530052
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of the JNK signaling pathway increases sensitivity of hepatocellular carcinoma cells to cisplatin by down-regulating expression of P-glycoprotein.
Liu XY; Liu SP; Jiang J; Zhang X; Zhang T
Eur Rev Med Pharmacol Sci; 2016; 20(6):1098-108. PubMed ID: 27049263
[TBL] [Abstract][Full Text] [Related]
27. Transcription Factor E2F8 Promotes Cisplatin Resistance in Hepatocellular Carcinoma by Regulating DNA Damage via NUSAP1.
Kong J; Xu S; Zhang P; Wang Y
Int J Toxicol; 2023; 42(5):420-429. PubMed ID: 37331996
[TBL] [Abstract][Full Text] [Related]
28. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis.
Chen S; Pu J; Bai J; Yin Y; Wu K; Wang J; Shuai X; Gao J; Tao K; Wang G; Li H
J Exp Clin Cancer Res; 2018 Jan; 37(1):3. PubMed ID: 29316949
[TBL] [Abstract][Full Text] [Related]
29. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.
Shi L; Xu Z; Wu G; Chen X; Huang Y; Wang Y; Jiang W; Ke B
BMC Cancer; 2017 Feb; 17(1):138. PubMed ID: 28202053
[TBL] [Abstract][Full Text] [Related]
30. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
31. Astragaloside IV enhances cisplatin chemosensitivity in hepatocellular carcinoma by suppressing MRP2.
Qu X; Gao H; Zhai J; Sun J; Tao L; Zhang Y; Song Y; Hu T
Eur J Pharm Sci; 2020 May; 148():105325. PubMed ID: 32259679
[TBL] [Abstract][Full Text] [Related]
32. Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines.
Zhuo L; Liu J; Wang B; Gao M; Huang A
Oncol Rep; 2013 Feb; 29(2):555-62. PubMed ID: 23229111
[TBL] [Abstract][Full Text] [Related]
33. Long non-coding RNA placenta‑specific protein 2 regulates the chemosensitivity of cancer cells to cisplatin in hepatocellular carcinoma (HCC) by sponging microRNA-96 to upregulate X-linked inhibitor of apoptosis protein.
Wang H; Zhang X; Chen X; Zhang S; Yun Z; Gao Q; Sheng H; Wang J
Bioengineered; 2022 Apr; 13(4):10765-10773. PubMed ID: 35475470
[TBL] [Abstract][Full Text] [Related]
34. IFI16 mis-localization can be a contributing factor to hepatocellular carcinoma progression.
Shi X; Liu J; Liu Q; Li M
Med Hypotheses; 2014 Mar; 82(3):398-400. PubMed ID: 24491427
[TBL] [Abstract][Full Text] [Related]
35. Circ_0030998 Restrains Cisplatin Resistance Through Mediating miR-1323/PDCD4 Axis in Non-small Cell Lung Cancer.
Zhu C; Jiang X; Xiao H; Guan J
Biochem Genet; 2022 Dec; 60(6):2434-2454. PubMed ID: 35460386
[TBL] [Abstract][Full Text] [Related]
36. MiR-155 targeting FoxO3a regulates oral cancer cell proliferation, apoptosis, and DDP resistance through targeting FoxO3a.
Li X; Liu K; Zhou W; Jiang Z
Cancer Biomark; 2020; 27(1):105-111. PubMed ID: 31771044
[TBL] [Abstract][Full Text] [Related]
37. Long non-coding RNA TPTEP1 inhibits hepatocellular carcinoma progression by suppressing STAT3 phosphorylation.
Ding H; Liu J; Zou R; Cheng P; Su Y
J Exp Clin Cancer Res; 2019 May; 38(1):189. PubMed ID: 31072375
[TBL] [Abstract][Full Text] [Related]
38. LINC00680 enhances hepatocellular carcinoma stemness behavior and chemoresistance by sponging miR-568 to upregulate AKT3.
Shu G; Su H; Wang Z; Lai S; Wang Y; Liu X; Dai L; Bi Y; Chen W; Huang W; Zhou Z; He S; Dai H; Tang B
J Exp Clin Cancer Res; 2021 Jan; 40(1):45. PubMed ID: 33499874
[TBL] [Abstract][Full Text] [Related]
39. Protein phosphatase 2A-B55δ enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b.
Zhuang Q; Zhou T; He C; Zhang S; Qiu Y; Luo B; Zhao R; Liu H; Lin Y; Lin Z
J Exp Clin Cancer Res; 2016 Apr; 35():67. PubMed ID: 27074866
[TBL] [Abstract][Full Text] [Related]
40. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
